We evidence reduced primary tumor growth associated with increased immune responses, reduced metastatic progression, and enhanced response to anti‐CTLA4 monotherapy in Foxp3‐fGFP mice when compared to WT controls. This evidence concerns the gene FOXP3 and neoplasm.